title: Myasthenia gravis: Association of British Neurologists' management guidelines.
abstract: Myasthenia gravis is an autoimmune disease of the neuromuscular junction for which many therapies were developed before the era of evidence based medicine. The basic principles of treatment are well known, however, patients continue to receive suboptimal treatment as a result of which a myasthenia gravis guidelines group was established under the aegis of The Association of British Neurologists. These guidelines attempt to steer a path between evidence-based practice where available, and established best practice where evidence is unavailable. Where there is insufficient evidence or a choice of options, the guidelines invite the clinician to seek the opinion of a myasthenia expert. The guidelines support clinicians not just in using the right treatments in the right order, but in optimising the use of well-known therapeutic agents. Clinical practice can be audited against these guidelines.
authors.affiliation: Department of Neurology, Greater Manchester Neuroscience Centre, Salford, Greater Manchester, UK.
authors.forename: Jon
authors.initials: J
authors.lastname: Sussman
authors.affiliation: Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK.
authors.forename: Maria E
authors.initials: ME
authors.lastname: Farrugia
authors.affiliation: Department of Neurology, Nottingham University Hospitals NHS Trust, Queens Medical Centre,Nottingham, Nottinghamshire, UK.
authors.forename: Paul
authors.initials: P
authors.lastname: Maddison
authors.affiliation: Department of Neurology, Morriston Hospital, Swansea, Wales, UK.
authors.forename: Marguerite
authors.initials: M
authors.lastname: Hill
authors.affiliation: Department of Neurology, John Radcliffe Hospital, Oxford, UK.
authors.forename: M Isabel
authors.initials: MI
authors.lastname: Leite
authors.affiliation: Department of Neurology, John Radcliffe Hospital, Oxford, UK.
authors.forename: David
authors.initials: D
authors.lastname: Hilton-Jones
mesh_terms: D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D019468:Disease Management; D006801:Humans; D009157:Myasthenia Gravis / Q000175:diagnosis* / Q000628:therapy*; D009462:Neurology / Q000379:methods* / Q000592:standards*; D011729:Pyridostigmine Bromide / Q000627:therapeutic use; D006113:United Kingdom
chemical_list: D002800:Cholinesterase Inhibitors; D011729:Pyridostigmine Bromide
keywords: MYASTHENIA